Lupus is an autoimmune disease in which people generate antibodies against their own organs. But when antibodies to phospholipid-binding proteins are involved, a variety of complications can occur.
Results from a study of epratuzumab were released today. It did not meet its primary endpoint of clinically reducing the severity of lupus in people with mild to moderate disease. The following is a statement from Sandra C. Raymond, President and CEO
Today, the U.S. House of Representatives passed the 21st Century Cures Act, legislation that has the potential to improve the drug development process and bring new and vital treatments forward for people with chronic diseases like lupus.